ArticleAJNR. American journal of neuroradiology2022
Quantifying T2-FLAIR Mismatch Using Geographically Weighted Regression and Predicting Molecular Status in Lower-Grade Gliomas.
Article in AJNR. American journal of neuroradiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- The immunotherapy advancement targeting malignant blastomas in early childhood.Frontiers in oncology · 2023Pooled it
- Core-based voxel-wise T2-FLAIR mismatch analysis for differentiation of IDH-mutant astrocytomas from oligodendrogliomas.Neuroradiology · 2026Article
- Deep learning-based quantification of T2-FLAIR mismatch sign: extending IDH mutation prediction in adult-type diffuse lower-grade glioma.European radiology · 2025Article
- The T2-FLAIR mismatch sign in oncologic neuroradiology: History, current use, emerging data, and future directions.The neuroradiology journal · 2024Review
- The 2021 World Health Organization Central Nervous System Tumor Classification: The Spectrum of Diffuse Gliomas.Biomedicines · 2024Review
- Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction.AJNR. American journal of neuroradiology · 2024Article
- Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.Neuroradiology · 2023Article
- Generalized Geographically Weighted Regression Model within a Modularized Bayesian Framework.Bayesian analysis · 2023Article
- A Pipeline for the Implementation and Visualization of Explainable Machine Learning for Medical Imaging Using Radiomics Features.Sensors (Basel, Switzerland) · 2022Article
- The 2021 World Health Organization classification of gliomas: an imaging approach.Radiologia brasileiraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
Abstract
background and purposeThe T2-FLAIR mismatch sign is a validated imaging sign of MATERIALS AND
methodsWe used multiparametric MR imaging scans and segmentation labels of 108 preoperative lower-grade glioma tumors from The Cancer Imaging Archive. Clinical information and T2-FLAIR mismatch sign labels were obtained from supplementary material of relevant publications. We adopted an objective analytic approach to estimate this sign through a geographically weighted regression and used the residuals for each case to construct a probability density function (serving as a residual signature). These functions were then analyzed using an appropriate statistical framework.
resultsWe observed statistically significant (
conclusionsOn the basis of this retrospective study, we show that geographically weighted regression-based residual signatures are highly informative of the T2-FLAIR mismatch sign and can identify
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.